These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 12957340)

  • 1. Understanding US addiction physicians' low rate of naltrexone prescription.
    Mark TL; Kranzler HR; Song X
    Drug Alcohol Depend; 2003 Sep; 71(3):219-28. PubMed ID: 12957340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using stated preference modeling to forecast the effect of medication attributes on prescriptions of alcoholism medications.
    Mark TL; Swait J
    Value Health; 2003; 6(4):474-82. PubMed ID: 12859589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of naltrexone for alcohol use disorders in the Veterans' Health Administration: a national study.
    Iheanacho T; Issa M; Marienfeld C; Rosenheck R
    Drug Alcohol Depend; 2013 Sep; 132(1-2):122-6. PubMed ID: 23434041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does family history of alcoholism moderate naltrexone's effects on alcohol use?
    Capone C; Kahler CW; Swift RM; O'Malley SS
    J Stud Alcohol Drugs; 2011 Jan; 72(1):135-40. PubMed ID: 21138720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-acting injectable depot naltrexone use in the Veterans' Health Administration: a national study.
    Marienfeld C; Iheanacho T; Issa M; Rosenheck RA
    Addict Behav; 2014 Feb; 39(2):434-8. PubMed ID: 23790742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey.
    Chen DT; Wynia MK; Moloney RM; Alexander GC
    Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1094-100. PubMed ID: 19697444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of naltrexone in the treatment of alcoholism nationally in the Department of Veterans Affairs.
    Petrakis IL; Leslie D; Rosenheck R
    Alcohol Clin Exp Res; 2003 Nov; 27(11):1780-4. PubMed ID: 14634494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Research to practice: adoption of naltrexone in alcoholism treatment.
    Thomas CP; Wallack SS; Lee S; McCarty D; Swift R
    J Subst Abuse Treat; 2003 Jan; 24(1):1-11. PubMed ID: 12646325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty.
    Mark TL; Kassed CA; Vandivort-Warren R; Levit KR; Kranzler HR
    Drug Alcohol Depend; 2009 Jan; 99(1-3):345-9. PubMed ID: 18819759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding Ohio X-Waivered Advanced Practice Registered Nurses' Rate of Naltrexone Prescription for Alcohol Use Disordered Patients.
    Wiggins M; Painter S; Burant C; Juratovac E; Alto K
    J Am Psychiatr Nurses Assoc; 2024; 30(3):613-623. PubMed ID: 36694460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Access to Addiction Pharmacotherapy in Private Health Plans.
    Reif S; Horgan CM; Hodgkin D; Matteucci AM; Creedon TB; Stewart MT
    J Subst Abuse Treat; 2016 Jul; 66():23-9. PubMed ID: 27211993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early adoption of injectable naltrexone for alcohol-use disorders: findings in the private-treatment sector.
    Abraham AJ; Roman PM
    J Stud Alcohol Drugs; 2010 May; 71(3):460-6. PubMed ID: 20409441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Barriers to the use of medications to treat alcoholism.
    Mark TL; Kranzler HR; Poole VH; Hagen CA; McLeod C; Crosse S
    Am J Addict; 2003; 12(4):281-94. PubMed ID: 14504021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescription procedures in medication for relapse prevention after inpatient treatment for alcohol use disorders in Switzerland.
    Buri C; Moggi F; Giovanoli A; Strik W
    Alcohol Alcohol; 2007; 42(4):333-9. PubMed ID: 17517820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naltrexone: A Pan-Addiction Treatment?
    Aboujaoude E; Salame WO
    CNS Drugs; 2016 Aug; 30(8):719-33. PubMed ID: 27401883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV Care Providers' Intentions to Prescribe and Actual Prescription of Pre-Exposure Prophylaxis to At-Risk Adolescents and Adults.
    Mullins TLK; Zimet G; Lally M; Xu J; Thornton S; Kahn JA
    AIDS Patient Care STDS; 2017 Dec; 31(12):504-516. PubMed ID: 29211514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Views about responsibility for alcohol addiction and negative evaluations of naltrexone.
    Johnson RA; Lukens JM; Kole JW; Sisti DA
    Subst Abuse Treat Prev Policy; 2015 Mar; 10():10. PubMed ID: 25886539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.
    Pettinati HM; O'Brien CP; Rabinowitz AR; Wortman SP; Oslin DW; Kampman KM; Dackis CA
    J Clin Psychopharmacol; 2006 Dec; 26(6):610-25. PubMed ID: 17110818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of dispensed disulfiram and naltrexone for alcoholism treatment in a veteran patient population.
    Hermos JA; Young MM; Gagnon DR; Fiore LD
    Alcohol Clin Exp Res; 2004 Aug; 28(8):1229-35. PubMed ID: 15318122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New chronic disease medication prescribing by nurse practitioners, physician assistants, and primary care physicians: a cohort study.
    Marcum ZA; Bellon JE; Li J; Gellad WF; Donohue JM
    BMC Health Serv Res; 2016 Jul; 16():312. PubMed ID: 27464570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.